ScientiaLux
Index
QF-Pro Home › QF-Pro Glossary › Clinical Applications › HNSCC
Cancer Type

HNSCC

A devastating cancer where checkpoint inhibitors are approved but better biomarkers are urgently needed.

View
Definition
Head and neck squamous cell carcinoma (HNSCC) encompasses cancers of the oral cavity, oropharynx, hypopharynx, and larynx. HNSCC is strongly associated with tobacco, alcohol, and HPV infection. Checkpoint inhibitorsLoading... (pembrolizumab, nivolumab) are approved for recurrent/metastatic HNSCC, but response rates are only 15-20% in unselected populations. PD-L1 expression (CPS 1) is used for patient selection but has limited predictive accuracy.
Video Segments
HER2/EGFR/HER3 Interactions in HNSCC
Primary
ICI Approved
Pembrolizumab, nivolumab
15-20%
Response rate (unselected)
HPV Status
Affects prognosis and response
CPS ≥1
Current selection threshold

HPV-Positive vs. HPV-Negative Disease

HNSCC is increasingly divided into two distinct diseases. HPV-positive oropharyngeal cancer (driven by HPV16) affects younger patients, has better prognosis, and shows higher immunotherapy response rates. HPV-negative HNSCC (tobacco/alcohol-associated) occurs in older patients with more comorbidities and poorer outcomes.

Both subtypes are approved for checkpoint inhibitorsLoading..., but biomarker-guided selection remains suboptimal. PD-L1 CPS (combined positive score) is used but doesn't fully predict response.

Simplified

Two Different Diseases: HPV-positive HNSCC (caused by virus) has better prognosis and different biology than HPV-negative (caused by smoking/alcohol).

Treatment Implication: Both respond to checkpoint inhibitors, but optimal patient selection strategies may differ between them.

The Need for Better Biomarkers

With only 15-20% response rates, most HNSCC patients receiving immunotherapy don't benefit. They experience immune-related adverse events and delayed access to potentially effective alternatives. Better biomarkers could identify the ~20% likely to respond.

Functional biomarkersLoading... measuring checkpoint engagement could address this gap. If PD-1/PD-L1 iFRETLoading... predicts response in HNSCC as it does in melanoma, patient selection could be dramatically improved.

Simplified

Current Situation: PD-L1 expression guides checkpoint inhibitor use in HNSCC, but prediction is imperfect.

Opportunity: Functional checkpoint measurement could potentially improve patient selection in both HPV-positive and HPV-negative populations.

CPS-Based Selection
PD-L1 CPS 1 qualifies for treatment (poor predictive value)
Engagement-Based Selection
Functional checkpoint measurement identifies true responders

Clinical Applications

  • Current standard: Pembrolizumab first-line for PD-L1 CPS 1 recurrent/metastatic HNSCC
  • HPV testing: Routine for oropharyngeal cancer (prognostic and predictive)
  • Biomarker development: Functional biomarkersLoading... could improve on CPS
  • Combination strategies: ICILoading... + chemotherapy, ICI + radiation under investigation

Connected Terms

Share This Term
Term Connections